褪黑素在治疗精神神经疾病方面的研究概述

孙小然,孙宏伟,孙琳

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (19) : 1660-1664.

PDF(712 KB)
PDF(712 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (19) : 1660-1664. DOI: 10.11669/cpj.2015.19.003
综述

褪黑素在治疗精神神经疾病方面的研究概述

  • 孙小然,孙宏伟,孙琳*
作者信息 +

Research Progress of Melatonin in the Treatment of Nerve Mental Illness

  • SUN Xiao-ran, SUN Hong-wei, SUN Lin*
Author information +
文章历史 +

摘要

精神及神经疾病病因复杂,尽管传统的理论和方法仍然是精神及神经疾病发病的主要机制和指导防治的主要理论基础,但这些理论已经不能充分解释抗精神病药物和抗神经病药物临床效应滞后现象。笔者查阅了近年来国内外研究文献,通过对褪黑素治疗精神及神经疾病的临床研究进行归纳总结后发现,褪黑素(melatonin, MT)与焦虑症、抑郁症、精神分裂症、恐怖症、等精神类疾病,以及与老年性痴呆、癫痫发作、帕金森病等神经类疾病密切相关。其在探索新型高效抗精神及神经疾病药物中具有巨大的潜力。

Abstract

Nerve mental illness has a complicated etiology. Although several hypotheses have been proposed, the etiology of this disorder is still unknown. In addition to the classical drugs that have been long proposed to the treatment of mental and neurological diseases, a strong association between melatonin and psychological disorder has been suggested in the light of several clinical and preclinical findings. In this review, some different hypotheses on pathophysiology mechanisms, the alterations of melatonin secretion and associated changes underlying mental and neurological diseases have been summarized. The causal relationships between melatonin and mental and neurological diseases are strongly supported by the efficacy of innovative.

关键词

褪黑素 / 生物节律 / 睡眠障碍 / 精神病 / 神经病

Key words

melatonin / biorhythm / sleep disorders / mental illness / neuropathy

引用本文

导出引用
孙小然,孙宏伟,孙琳. 褪黑素在治疗精神神经疾病方面的研究概述[J]. 中国药学杂志, 2015, 50(19): 1660-1664 https://doi.org/10.11669/cpj.2015.19.003
SUN Xiao-ran, SUN Hong-wei, SUN Lin. Research Progress of Melatonin in the Treatment of Nerve Mental Illness[J]. Chinese Pharmaceutical Journal, 2015, 50(19): 1660-1664 https://doi.org/10.11669/cpj.2015.19.003
中图分类号: R964    R749.053    R338   

参考文献

[1] BALTACI A K, BEDIZ C S, MOGULKOC R, et al. Effect of zinc and melatonin supplementation on cellular immunity in rats with toxoplasmosis[J]. Biol Trace Elem Res, 2003, 96(1-3):237-245.
[2] CARRILLO-VICO A, LARDONE P J, NAJI L, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice:Regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects[J]. J Pineal Res, 2005, 39(4):400-408.
[3] SANDYK R. The accelerated aging hypothesis of Parkinson′s disease is not supported by the pattern of circadian melatonin secretion [J]. Int J Neurosci, 1997, 90(3-4):271-275.
[4] CABEZA J, MOTILVA V, MARTN M J, et al. Mechanisms involved in gastric protection of melatonin against oxidant stress by ischemia-reperfusion in rats[J]. Life Sci, 2001, 68(12):1405-1415.
[5] COMAI S, OCHOA-SANCHEZ R, DOMINGUEZ-LOPEZ S, et al. Melancholic-Like behaviors and circadian neurobiological abnormalities in melatonin MT1 receptor knockout mice[J]. Int J Neuropsychopharmacol, 2015, 18(3):pyu075.
[6] BUSTAMANTE-GARCIA R, NARANJO-RODRGUEZ E B, LIRA-ROCHA A S, et al. Behavioural actions of two new 1-N substituted analogues of melatonin[J]. Behav Brain Res, 2013, 236(1):148-156.
[7] REITER R J, SAINZ R M, LOPEZ-BURILLO S, et al, Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke[J]. Ann N Y Acad Sci, 2003, 993:35-47.
[8] TORII K, UNEYAMA H, NISHINO H, et al. Melatonin suppresses cerebral edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by magnetic resonance imaging[J]. J Pineal Res, 2004, 36(1):18-24.
[9] BIENERT A, WAWRZYNIAK K, WICZLING P, et al. Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions[J]. J Clin Pharmacol, 2014,55(3):307-316.
[10] ADAMAH-BIASSI E B, HUDSON R L, DUBOCOVICH M L. Genetic deletion of MT melatonin receptors alters spontaneous behavioral rhythms in male and female C57BL/6 mice[J]. Horm Behav, 2014, 66(4):619-627.
[11] KUMAR A, KAUR G, RINWA P. Buspirone along with melatonin attenuates oxidative damage and anxiety-like behavior in a mouse model of immobilization stress[J]. Chin J Nat Med(中国天然药物), 2014, 12(8):582-589.
[12] HUANG F L, YANG Z H, LIU X Y, et al. Melatonin facilitates extinction, but not acquisition or expression, of conditional cued fear in rats[J]. BMC Neurosci, 2014, 15:86.
[13] ARUSHANIAN E B. Melatonin as a drug:present status and perspectives[J]. Eksp Klin Farmakol, 2014, 77(6):39-44.
[14] HUANG H W, JIANG L, SHEN L, et al. Impact of oral melatonin on critically ill adult patients with ICU sleep deprivation:study protocol for a randomized controlled trial[J]. Trials, 2014, 15:327.
[15] AZIRIOVA S, REPOVA BEDNAROVA K, KRAJCIROVICOVA K, et al. Doxorubicin-induced behavioral disturbances in rats:protective effect of melatonin and captopril[J]. Pharmacol Biochem Behav, 2014, 124:284-289.
[16] KHEZRI M B, OLADI M R, ATLASBAF A. Effect of melatonin and gabapentin on anxiety and pain associated with retrobulbar eye block for cataract surgery:a randomized double-blind study[J]. Indian J Pharmacol, 2013, 45(6):581-586.
[17] HANSEN M V, ANDERSEN L T, MADSEN M T,et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery:a randomized, double-blind, placebo-controlled trial[J]. Breast Cancer Res Treat, 2014, 145(3):683-695.
[18] BUSTAMANTE-GARCA R, LIRA-ROCHA A S, ESPEJO-GONZLEZ O, et al. Anxiolytic-like effects of a new 1-N substituted analog of melatonin in pinealectomized rats[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2014, 51:133-139.
[19] HUANG Y L, LIANG X B, QIAN L Q, et al. Effects of kaixin powder on melatonin receptor expression and I-Mel binding affinity in a rat model of depression[J]. Chin J Integr Med(中国结合医学杂志), 2015,21(7):507-515.
[20] WEHR T A, JACOBSEN F M, SACK D A, et al. Phototherapy of seasonal affective disorder. Time of day and suppression of melatonin are not critical for antidepressant effects[J]. Arch Gen Psychiatry, 1986, 43(9):870-875.
[21] ROSENTHAL N E, SMITS M, SPENCE W, et al. Melatonin in seasonal affective disorder and phototherapy[J]. J Neural Transm Suppl, 1986, 21:257-267.
[22] GARDNER C. Creating the right light for older people[J]. Health Estate, 2014, 68(8):62-66.
[23] HANSEN M V, DANIELSEN A K, HAGEMAN I, et al. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms:a systematic review and meta-analysis[J]. Eur Neuropsychopharmacol, 2014, 24(11):1719-1728.
[24] ADAMCZYK-SOWA M, PIERZCHALA K, SOWA P, et al. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients[J]. J Physiol Pharmacol, 2014, 65(4):543-550.
[25] QUERA SALVA M A, HARTLEY S, BARBOT F, et al. Circadian rhythms, melatonin and depression[J]. Curr Pharm Des, 2011, 17(15):1459-1470.
[26] LEWY A J, LEFLER B J, EMENS J S, et al. The circadian basis of winter depression[J]. Proc Natl Acad Sci USA, 2006, 103(19):7414-7419.
[27] HERRN R, FRIEDLAND A. Medical normativity in the diagnosis of schizophrenia at the Charite′ Hospital around 1920. An application of Grounded Theory to historical patient records[J]. Medizinhist J, 2012, 47(4):257-295.
[28] ALTSCHULE M D. Some effects of aqueous extracts of acetone-dried beef-pineal substance in chronic schizophrenia[J]. N Engl J Med, 1957, 257(19):919-922.
[29] BIGELOW L B. Effects of aqueous pineal extract in chronic schizophrenia[J]. Biol Psychiatry, 1974, 8(1):5-15.
[30] MODABBERNIA A, HEIDARI P, SOLEIMANI R, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia:randomized double-blind placebo-controlled study[J]. J Psychiatr Res, 2014, 53:133-140.
[31] DE RUI M, MIDDLETON B, STICCA A, et al. Sleep and circadian rhythms in hospitalized patients with decompensated cirrhosis: effect of light therapy[J]. Neurochem Res, 2014, 40(2):284-292.
[32] ANDERSON G, MAES M. Local melatonin regulates inflammation resolution:a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders[J]. CNS Neurol Disord Drug Targets, 2014, 13(5):817-827.
[33] LAUDON M, FRYDMAN-MAROM A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders[J]. Int J Mol Sci, 2014, 15(9):15924-15950.
[34] JOHNSA J D, NEVILLE M W. Tasimelteon: a melatonin receptor agonist for non-24 sleep-wake disorder[J]. Ann Pharmacother, 2014, 48(12):1636-1641.
[35] ROMO-NAVA F, ALVAREZ-ICAZA GONZLEZ D, FRESN-ORELLANA A, et al. Melatonin attenuates antipsychotic metabolic effects:an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial[J]. Bipolar Disord, 2014, 16(4):410-421.
[36] LIN L, DU Y, YUAN S, et al. Serum melatonin is an alternative index of Parkinson′s disease severity[J]. Brain Res, 2014, 1547:43-48.
[37] SINGHAL N K, CHAUHAN A K, JAIN S K, et al. Silymarin- and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism[J]. Mol Cell Biochem, 2013, 384(1-2):47-58.
[38] DATIEVA V K, ROSINSKAIA A V, LEVIN O S. The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson′s disease [J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2013, 113(7 Pt 2):77-81.
[39] LEHTINEN E K, UCAR E, GLENTHJ B Y, et al. Effects of melatonin on prepulse inhibition, habituation and sensitization of the human startle reflex in healthy volunteers[J]. Psychiatry Res, 2014, 216(3):418-423.
[40] MORERA-FUMERO A L, ABREU-GONZALEZ P. Role of melatonin in schizophrenia[J]. Int J Mol Sci, 2013, 14(5):9037-9050.
[41] ANDERSON G, MAES M. Melatonin:an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects[J]. Metab Brain Dis, 2012, 27(2):113-119.
[42] ARUSHANIAN E B, CHERNYSHEVA E M. The comparative effect of melatonin and diazepam on shifts in the anxiety-phobia status of rats evoked by damage to the amygdala [J]. Eksp Klin Farmakol, 1997, 60(1):7-9.
[43] SOTO-MOYANO R, BURGOS H, FLORES F, et al. Melatonin administration impairs visuo-spatial performance and inhibits neocortical long-term potentiation in rats[J]. Pharmacol Biochem Behav, 2006, 85(2):408-414.
[44] SONG T Y, LIN H C, CHEN C L, et al. Ergothioneine and melatonin attenuate oxidative stress and protect against learning and memory deficits in C57BL/6J mice treated with D-galactose[J]. Free Radic Res, 2014, 48(9):1049-1060.
[45] DI PAOLO C, REVERTE I, COLOMINA M T, et al. Chronic exposure to aluminum and melatonin through the diet:Neurobehavioral effects in a transgenic mouse model of Alzheimer disease[J]. Food Chem Toxicol, 2014, 69:320-329.
[46] LOPEZ-IGLESIAS B, PREZ C, MORALES-GARCA J A, et al. New melatonin-N, N-dibenzyl(N-methyl)amine hybrids:potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer′s disease[J]. J Med Chem, 2014, 57(9):3773-3785.
[47] COMAI S, GOBBI G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases:a novel target in psychopharmacology[J]. J Psychiatry Neurosci, 2014, 39(1):6-21.
[48] GIUSTI P, LIPARTITI M, FRANCESCHINI D, et al. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats[J]. Faseb J, 1996, 10(8):891-896.
[49] SANCHEZ-BARCELO E J, MEDIAVILLA M D, REITER R J. Clinical uses of melatonin in pediatrics[J]. Int J Pediatr, 2011, 58(9):892624.
[50] CHENG X L, CHEN J, LI M H, et al. Identificantion study of glue medicines[J]. Chin Pharm J(中国药学杂志),2015,50(2):104-108.
[51] BANACH M, GURDZIEL E, JEDRYCH M, et al. Melatonin in experimental seizures and epilepsy[J]. Pharmacol Rep, 2011,63(1):1-11.
[52] LOW V, BEN-SHLOMO Y, COWARD E, et al. Measuring the burden and mortality of hospitalisation in Parkinson′s disease:a cross-sectional analysis of the English Hospital Episodes Statistics database 2009-2013[J]. Parkinsonism Relat Disord, 2015, 21(5):449-454.
[53] PERTSOV S S, KOPLIK E V, KALINICHENKO L S, et al. Effect of melatonin on lipid peroxidation in the blood of rats with various behavioral characteristics during acute emotional stress [J]. Ross Fiziol Zh Im I M Sechenova, 2014, 100(6):759-766.
[54] OGUZ E, YILMAZ Z, OZBILGE H, et al. Effects of melatonin on the serum levels of pro-inflammatory cytokines and tissue injury after renal ischemia reperfusion in rats[J]. Ren Fail, 2015, 37(2):318-322.

基金

山东省优秀中青年科学家科研奖励基金资助项目(BS2014YY043);潍坊医学院科技创新研究基金重点资助项目(K1301011)
PDF(712 KB)

56

Accesses

0

Citation

Detail

段落导航
相关文章

/